Gene symbol   |
Time course plot |
Accession |
Description |
Treatment |
15min |
30min |
1hr |
2hr |
4hr |
8hr |
20hr |
Adcy1 |  |
BC050125 |
adenylate cyclase 1, mRNA (cDNA clone IMAGE:30015692). [BC050125] |
KLA | 1.05 |
1.03 |
.98 |
1.04 |
1.05 |
1.09 |
1.10 |
| ATP | .90 |
1.02 |
.99 |
.97 |
1.03 |
.95 |
1.01 |
| KLA/ATP | .99 |
1.04 |
.90 |
.98 |
.98 |
1.00 |
1.03 |
|
Adcy1 |  |
NM_009622 |
adenylate cyclase 1 (Adcy1), mRNA [NM_009622] |
KLA | 1.07 |
1.02 |
1.06 |
1.07 |
1.03 |
1.02 |
1.01 |
| ATP | 1.02 |
1.04 |
1.00 |
.99 |
.99 |
.95 |
.97 |
| KLA/ATP | .97 |
1.05 |
1.02 |
1.05 |
1.01 |
.98 |
1.05 |
|
Adcy2 |  |
NM_153534 |
adenylate cyclase 2 (Adcy2), mRNA [NM_153534] |
KLA | .79 |
.82 |
.83 |
.73 |
.61 |
.66 |
.90 |
| ATP | 1.10 |
1.09 |
1.02 |
1.04 |
.88 |
.58 |
.53 |
| KLA/ATP | .84 |
.87 |
.77 |
.75 |
.68 |
.60 |
.43 |
|
Adcy3 |  |
NM_138305 |
adenylate cyclase 3 (Adcy3), mRNA [NM_138305] |
KLA | .84 |
.84 |
.83 |
.78 |
.66 |
.55 |
.49 |
| ATP | 1.09 |
1.05 |
.89 |
1.02 |
.84 |
.62 |
1.52 |
| KLA/ATP | .93 |
.87 |
.75 |
.85 |
.66 |
.83 |
.77 |
|
Adcy4 |  |
NM_080435 |
adenylate cyclase 4 (Adcy4), mRNA [NM_080435] |
KLA | 1.05 |
1.07 |
.96 |
1.00 |
1.04 |
1.05 |
1.05 |
| ATP | 1.02 |
1.05 |
1.02 |
1.48 |
1.37 |
1.08 |
1.09 |
| KLA/ATP | 1.00 |
1.05 |
.91 |
1.19 |
1.35 |
1.27 |
1.08 |
|
Adcy5 |  |
NM_001012765 |
adenylate cyclase 5 (Adcy5), mRNA [NM_001012765] |
KLA | 1.06 |
1.00 |
.97 |
1.01 |
1.03 |
.95 |
.93 |
| ATP | .95 |
1.08 |
1.08 |
1.07 |
.97 |
1.03 |
.97 |
| KLA/ATP | .97 |
.92 |
1.04 |
.99 |
.91 |
.96 |
1.04 |
|
Adcy6 |  |
NM_007405 |
adenylate cyclase 6 (Adcy6), mRNA [NM_007405] |
KLA | 1.10 |
1.16 |
1.16 |
1.09 |
1.08 |
1.06 |
.99 |
| ATP | 1.05 |
.97 |
1.08 |
1.12 |
1.08 |
1.08 |
1.04 |
| KLA/ATP | 1.14 |
1.20 |
1.29 |
1.30 |
1.25 |
1.11 |
1.07 |
|
Adcy7 |  |
NM_001037724 |
adenylate cyclase 7 (Adcy7), transcript variant 3, mRNA [NM_001037724] |
KLA | .43 |
.39 |
.35 |
.32 |
.45 |
.72 |
.84 |
| ATP | .90 |
.84 |
.62 |
.41 |
.53 |
.42 |
.94 |
| KLA/ATP | .39 |
.34 |
.23 |
.17 |
.41 |
.34 |
.67 |
|
Adcy7 |  |
NM_007406 |
adenylate cyclase 7 (Adcy7), transcript variant 1, mRNA [NM_007406] |
KLA | .51 |
.52 |
.48 |
.41 |
.59 |
.81 |
.99 |
| ATP | 1.01 |
1.02 |
.62 |
.52 |
.53 |
.38 |
.98 |
| KLA/ATP | .53 |
.48 |
.30 |
.27 |
.42 |
.36 |
.65 |
|
Adcy8 |  |
NM_009623 |
adenylate cyclase 8 (Adcy8), mRNA [NM_009623] |
KLA | 1.00 |
1.00 |
1.07 |
.97 |
1.04 |
.98 |
1.02 |
| ATP | 1.04 |
1.05 |
1.14 |
1.03 |
.99 |
1.00 |
.97 |
| KLA/ATP | 1.05 |
1.04 |
1.00 |
1.03 |
.98 |
.94 |
.96 |
|
Adcy9 |  |
NM_009624 |
adenylate cyclase 9 (Adcy9), mRNA [NM_009624] |
KLA | .18 |
.15 |
.13 |
.15 |
.17 |
.19 |
.33 |
| ATP | 1.33 |
1.16 |
.97 |
.98 |
.62 |
.56 |
.86 |
| KLA/ATP | .19 |
.16 |
.17 |
.18 |
.20 |
.25 |
.38 |
|
Akt1 |  |
NM_009652 |
thymoma viral proto-oncogene 1 (Akt1), mRNA [NM_009652] |
KLA | .80 |
.80 |
.75 |
.75 |
.71 |
.70 |
.82 |
| ATP | 1.00 |
1.02 |
.76 |
.85 |
.76 |
.68 |
.84 |
| KLA/ATP | .82 |
.80 |
.64 |
.68 |
.67 |
.61 |
.72 |
|
Akt2 |  |
NM_007434 |
thymoma viral proto-oncogene 2 (Akt2), transcript variant 2, mRNA [NM_007434] |
KLA | 1.45 |
1.49 |
1.81 |
1.61 |
1.83 |
1.17 |
.92 |
| ATP | 1.12 |
1.12 |
1.00 |
1.28 |
1.20 |
.94 |
1.06 |
| KLA/ATP | 1.48 |
1.70 |
1.69 |
1.58 |
1.57 |
1.32 |
1.27 |
|
Akt3 |  |
NM_011785 |
thymoma viral proto-oncogene 3 (Akt3), mRNA [NM_011785] |
KLA | 3.42 |
3.45 |
5.31 |
5.16 |
4.65 |
3.80 |
2.12 |
| ATP | 1.12 |
1.22 |
1.10 |
1.37 |
1.02 |
1.11 |
1.56 |
| KLA/ATP | 3.72 |
4.17 |
4.62 |
4.64 |
2.74 |
2.05 |
3.82 |
|
Atf2 |  |
AK047405 |
10 days neonate cerebellum cDNA, RIKEN full-length enriched library, clone:B930056P03 product:activating transcription factor 2, full insert sequence. [AK047405] |
KLA | 1.01 |
1.00 |
1.02 |
1.04 |
1.03 |
1.03 |
1.00 |
| ATP | .99 |
1.00 |
.95 |
1.01 |
1.04 |
.98 |
1.03 |
| KLA/ATP | 1.07 |
1.00 |
.98 |
.99 |
1.00 |
1.03 |
.93 |
|
Atf2 |  |
NM_001025093 |
activating transcription factor 2 (Atf2), transcript variant 1, mRNA [NM_001025093] |
KLA | 1.35 |
1.30 |
1.32 |
1.31 |
1.37 |
1.09 |
1.20 |
| ATP | 1.15 |
1.17 |
.99 |
1.11 |
1.22 |
1.39 |
1.28 |
| KLA/ATP | 1.38 |
1.42 |
1.21 |
1.28 |
1.17 |
1.33 |
1.69 |
|
Atf4 |  |
NM_009716 |
activating transcription factor 4 (Atf4), mRNA [NM_009716] |
KLA | .91 |
1.06 |
1.13 |
1.31 |
1.92 |
2.59 |
3.01 |
| ATP | 1.05 |
1.14 |
1.34 |
2.88 |
4.84 |
2.36 |
2.56 |
| KLA/ATP | 1.14 |
1.08 |
1.17 |
2.40 |
3.72 |
3.54 |
3.62 |
|
BB548379
|  |
BB548379 |
gb|BB548379 RIKEN full-length enriched, 2 days pregnant adult female oviduct Mus musculus cDNA clone E230007L20 3. [BB548379] |
KLA | .98 |
1.05 |
1.00 |
.99 |
1.04 |
1.04 |
1.05 |
| ATP | 1.01 |
.98 |
1.01 |
1.02 |
.98 |
1.08 |
.92 |
| KLA/ATP | .98 |
1.06 |
1.03 |
1.03 |
1.00 |
1.00 |
.99 |
|
Calm1 |  |
NM_009790 |
calmodulin 1 (Calm1), mRNA [NM_009790] |
KLA | 1.20 |
1.26 |
1.30 |
1.06 |
1.16 |
1.09 |
1.18 |
| ATP | 1.07 |
1.20 |
1.00 |
1.29 |
.99 |
.64 |
.58 |
| KLA/ATP | 1.31 |
1.31 |
.93 |
1.31 |
.97 |
.83 |
.59 |
|
Calm2 |  |
NM_007589 |
calmodulin 2 (Calm2), mRNA [NM_007589] |
KLA | .79 |
.81 |
.71 |
.67 |
.54 |
.45 |
.64 |
| ATP | .99 |
1.03 |
1.04 |
.93 |
.82 |
.52 |
.76 |
| KLA/ATP | .76 |
.78 |
.76 |
.77 |
.73 |
.47 |
.42 |
|
Calm3 |  |
NM_007590 |
calmodulin 3 (Calm3), mRNA [NM_007590] |
KLA | .95 |
.96 |
.93 |
1.03 |
1.05 |
1.08 |
1.00 |
| ATP | .93 |
.96 |
.99 |
.97 |
.93 |
.84 |
.72 |
| KLA/ATP | .89 |
.93 |
.90 |
.91 |
1.02 |
.98 |
.70 |
|
Calm4 |  |
NM_020036 |
calmodulin 4 (Calm4), mRNA [NM_020036] |
KLA | 1.02 |
.96 |
1.05 |
1.00 |
.99 |
1.00 |
1.01 |
| ATP | 1.10 |
1.05 |
1.03 |
1.01 |
.94 |
.98 |
.98 |
| KLA/ATP | .99 |
1.12 |
1.01 |
1.03 |
.98 |
1.07 |
1.02 |
|
Calm5 |  |
NM_001008706 |
calmodulin 5 (Calm5), mRNA [NM_001008706] |
KLA | 1.02 |
1.11 |
.99 |
.98 |
1.07 |
1.01 |
1.09 |
| ATP | 1.07 |
1.05 |
1.04 |
1.04 |
1.01 |
1.04 |
.99 |
| KLA/ATP | 1.00 |
1.00 |
.97 |
1.07 |
1.00 |
1.07 |
.98 |
|
Calml3 |  |
NM_027416 |
calmodulin-like 3 (Calml3), mRNA [NM_027416] |
KLA | 1.01 |
.95 |
1.05 |
.91 |
1.01 |
.98 |
.89 |
| ATP | .91 |
1.05 |
1.04 |
1.01 |
.93 |
1.07 |
.99 |
| KLA/ATP | 1.01 |
.96 |
.97 |
.96 |
.97 |
.92 |
.99 |
|
Creb1 |  |
NM_009952 |
cAMP responsive element binding protein 1 (Creb1), transcript variant B, mRNA [NM_009952] |
KLA | 1.42 |
1.33 |
1.16 |
.99 |
.83 |
.97 |
.92 |
| ATP | .92 |
.91 |
1.18 |
1.38 |
1.51 |
1.02 |
.75 |
| KLA/ATP | 1.34 |
1.31 |
1.49 |
1.37 |
1.71 |
1.05 |
.93 |
|
Creb3 |  |
NM_013497 |
cAMP responsive element binding protein 3 (Creb3), mRNA [NM_013497] |
KLA | 1.21 |
1.21 |
1.23 |
1.53 |
1.77 |
1.77 |
1.31 |
| ATP | 1.02 |
1.03 |
.99 |
1.05 |
.82 |
.83 |
1.48 |
| KLA/ATP | 1.15 |
1.18 |
1.20 |
1.26 |
1.13 |
1.15 |
1.86 |
|
Creb3l1 |  |
NM_011957 |
cAMP responsive element binding protein 3-like 1 (Creb3l1), mRNA [NM_011957] |
KLA | 1.18 |
1.17 |
1.53 |
1.28 |
1.22 |
1.11 |
1.23 |
| ATP | 1.01 |
1.09 |
.98 |
1.17 |
1.22 |
1.01 |
1.15 |
| KLA/ATP | 1.22 |
1.29 |
1.08 |
1.34 |
1.14 |
1.36 |
1.12 |
|
Creb3l2 |  |
AK082964 |
12 days embryo spinal cord cDNA, RIKEN full-length enriched library, clone:C530025K05 product:unclassifiable, full insert sequence [AK082964] |
KLA | .44 |
.38 |
.37 |
.40 |
.45 |
.42 |
.47 |
| ATP | .90 |
.78 |
1.22 |
.79 |
.54 |
.46 |
.44 |
| KLA/ATP | .41 |
.41 |
.49 |
.43 |
.50 |
.51 |
.23 |
|
Creb3l2 |  |
NM_178661 |
cAMP responsive element binding protein 3-like 2 (Creb3l2), mRNA [NM_178661] |
KLA | .98 |
.87 |
.76 |
.98 |
1.03 |
.87 |
1.12 |
| ATP | 1.20 |
1.18 |
1.50 |
1.35 |
.86 |
1.32 |
1.50 |
| KLA/ATP | .98 |
1.04 |
1.15 |
1.05 |
.79 |
1.27 |
1.25 |
|
Creb3l3 |  |
NM_145365 |
cAMP responsive element binding protein 3-like 3 (Creb3l3), mRNA [NM_145365] |
KLA | .66 |
.75 |
.65 |
.85 |
1.04 |
1.44 |
1.73 |
| ATP | 1.02 |
.98 |
.97 |
1.09 |
.85 |
.69 |
1.11 |
| KLA/ATP | .70 |
.66 |
.71 |
.83 |
.80 |
.85 |
1.05 |
|
Creb3l4 |  |
NM_030080 |
cAMP responsive element binding protein 3-like 4 (Creb3l4), mRNA [NM_030080] |
KLA | 1.55 |
1.42 |
1.51 |
1.73 |
1.76 |
2.54 |
1.38 |
| ATP | 1.07 |
.81 |
.89 |
1.08 |
.94 |
1.08 |
1.08 |
| KLA/ATP | 1.44 |
1.38 |
1.44 |
1.25 |
1.30 |
1.26 |
2.24 |
|
Creb5 |  |
AK051306 |
12 days embryo spinal ganglion cDNA, RIKEN full-length enriched library, clone:D130032G03 product:unclassifiable, full insert sequence. [AK051306] |
KLA | 2.18 |
2.13 |
2.42 |
1.97 |
1.57 |
1.94 |
1.98 |
| ATP | 1.11 |
1.09 |
1.47 |
1.74 |
1.36 |
1.44 |
1.62 |
| KLA/ATP | 2.55 |
2.77 |
3.02 |
3.15 |
2.51 |
2.52 |
2.61 |
|
Creb5 |  |
NM_172728 |
cAMP responsive element binding protein 5 (Creb5), mRNA [NM_172728] |
KLA | 3.70 |
3.60 |
2.84 |
2.39 |
1.92 |
2.81 |
1.84 |
| ATP | .92 |
.89 |
1.19 |
1.93 |
1.51 |
1.55 |
1.44 |
| KLA/ATP | 3.16 |
3.51 |
4.33 |
5.35 |
5.78 |
3.23 |
3.03 |
|
Crebl1 |  |
NM_017406 |
cAMP responsive element binding protein-like 1 (Crebl1), mRNA [NM_017406] |
KLA | 1.22 |
1.30 |
1.32 |
1.34 |
1.51 |
1.52 |
1.75 |
| ATP | 1.13 |
1.32 |
1.16 |
1.66 |
1.06 |
.93 |
1.54 |
| KLA/ATP | 1.37 |
1.25 |
1.21 |
1.74 |
1.04 |
1.01 |
2.07 |
|
Egfr |  |
NM_007912 |
epidermal growth factor receptor (Egfr), transcript variant 2, mRNA [NM_007912] |
KLA | 1.10 |
1.07 |
1.14 |
1.11 |
1.08 |
1.03 |
.90 |
| ATP | .99 |
1.00 |
1.04 |
.98 |
.97 |
1.15 |
1.14 |
| KLA/ATP | 1.07 |
1.10 |
1.16 |
1.08 |
1.01 |
.97 |
.94 |
|
Egfr |  |
NM_207655 |
epidermal growth factor receptor (Egfr), transcript variant 1, mRNA [NM_207655] |
KLA | 1.57 |
1.44 |
1.47 |
1.31 |
.96 |
.92 |
.76 |
| ATP | .97 |
.93 |
1.10 |
1.00 |
1.41 |
2.97 |
.86 |
| KLA/ATP | 1.44 |
1.50 |
1.61 |
1.30 |
1.14 |
1.21 |
.82 |
|
Esr1 |  |
NM_007956 |
estrogen receptor 1 (alpha) (Esr1), mRNA [NM_007956] |
KLA | 1.06 |
1.05 |
1.11 |
1.36 |
1.33 |
1.02 |
.90 |
| ATP | 1.05 |
.92 |
1.02 |
.94 |
1.02 |
.83 |
.67 |
| KLA/ATP | 1.02 |
.98 |
1.09 |
1.08 |
1.32 |
1.07 |
.71 |
|
Esr2 |  |
NM_207707 |
estrogen receptor 2 (beta) (Esr2), transcript variant 1, mRNA [NM_207707] |
KLA | 1.00 |
1.00 |
1.01 |
1.00 |
1.00 |
1.01 |
1.02 |
| ATP | .99 |
1.00 |
1.00 |
1.00 |
1.00 |
1.01 |
1.01 |
| KLA/ATP | 1.00 |
1.02 |
.98 |
.97 |
1.01 |
.99 |
1.00 |
|
Fkbp4 |  |
NM_010219 |
FK506 binding protein 4 (Fkbp4), mRNA [NM_010219] |
KLA | .82 |
.87 |
.90 |
.71 |
.67 |
.55 |
.77 |
| ATP | .99 |
1.09 |
1.06 |
1.30 |
1.04 |
.58 |
.55 |
| KLA/ATP | .89 |
.89 |
.83 |
.93 |
.77 |
.59 |
.33 |
|
Fkbp5 |  |
NM_010220 |
FK506 binding protein 5 (Fkbp5), mRNA [NM_010220] |
KLA | .96 |
1.02 |
.97 |
.89 |
.71 |
.69 |
.60 |
| ATP | 1.02 |
1.06 |
1.02 |
1.00 |
.96 |
1.04 |
.70 |
| KLA/ATP | 1.03 |
.99 |
.90 |
.98 |
.84 |
.86 |
.67 |
|
Fos |  |
NM_010234 |
FBJ osteosarcoma oncogene (Fos), mRNA [NM_010234] |
KLA | .42 |
.33 |
.64 |
.61 |
.71 |
.85 |
.71 |
| ATP | 3.48 |
5.46 |
23.78 |
25.22 |
1.71 |
2.36 |
1.50 |
| KLA/ATP | .90 |
1.74 |
5.97 |
8.62 |
1.28 |
2.42 |
4.52 |
|
Gabbr1 |  |
NM_019439 |
gamma-aminobutyric acid (GABA-B) receptor, 1 (Gabbr1), mRNA [NM_019439] |
KLA | 1.00 |
1.03 |
1.04 |
1.01 |
.97 |
1.01 |
.99 |
| ATP | .98 |
.96 |
1.03 |
1.01 |
.96 |
1.03 |
.99 |
| KLA/ATP | .97 |
1.00 |
.97 |
1.02 |
1.02 |
.97 |
1.01 |
|
Gabbr2 |  |
NM_001081141 |
gamma-aminobutyric acid (GABA) B receptor 2 (Gabbr2), mRNA [NM_001081141] |
KLA | 1.06 |
.98 |
.99 |
1.03 |
1.09 |
1.06 |
1.02 |
| ATP | 1.03 |
1.06 |
1.05 |
1.14 |
1.10 |
1.00 |
1.04 |
| KLA/ATP | 1.09 |
1.10 |
1.12 |
1.11 |
1.06 |
1.04 |
1.06 |
|
Gnai1 |  |
NM_010305 |
guanine nucleotide binding protein (G protein), alpha inhibiting 1 (Gnai1), mRNA [NM_010305] |
KLA | .95 |
1.01 |
1.01 |
1.00 |
1.09 |
1.10 |
1.08 |
| ATP | 1.06 |
1.06 |
.99 |
1.15 |
1.02 |
.94 |
.99 |
| KLA/ATP | 1.02 |
1.04 |
.99 |
1.16 |
1.01 |
1.02 |
1.13 |
|
Gnai2 |  |
NM_008138 |
guanine nucleotide binding protein (G protein), alpha inhibiting 2 (Gnai2), mRNA [NM_008138] |
KLA | .74 |
.79 |
.82 |
.74 |
.91 |
.97 |
1.10 |
| ATP | 1.07 |
1.16 |
.78 |
1.12 |
.78 |
.48 |
.82 |
| KLA/ATP | .91 |
.81 |
.53 |
.80 |
.60 |
.68 |
.87 |
|
Gnai3 |  |
NM_010306 |
guanine nucleotide binding protein (G protein), alpha inhibiting 3 (Gnai3), mRNA [NM_010306] |
KLA | 1.23 |
1.24 |
1.14 |
1.06 |
.99 |
1.15 |
1.09 |
| ATP | .96 |
.93 |
.86 |
.64 |
1.34 |
2.02 |
1.35 |
| KLA/ATP | 1.20 |
1.24 |
.97 |
.76 |
1.21 |
1.62 |
1.17 |
|
Gnao1 |  |
NM_001113384 |
guanine nucleotide binding protein, alpha O (Gnao1), transcript variant B, mRNA [NM_001113384] |
KLA | .95 |
.98 |
1.03 |
1.00 |
1.02 |
1.02 |
.99 |
| ATP | .95 |
1.02 |
1.01 |
1.08 |
.99 |
.97 |
.95 |
| KLA/ATP | 1.05 |
1.04 |
1.10 |
.99 |
1.01 |
.98 |
1.03 |
|
Gnao1 |  |
NM_010308 |
guanine nucleotide binding protein, alpha O (Gnao1), transcript variant A, mRNA [NM_010308] |
KLA | .98 |
.96 |
1.00 |
.97 |
.96 |
.97 |
1.01 |
| ATP | 1.12 |
.99 |
1.05 |
.87 |
.97 |
1.02 |
1.01 |
| KLA/ATP | .93 |
1.00 |
.99 |
1.01 |
1.05 |
1.07 |
.98 |
|
Gnaq |  |
NM_008139 |
guanine nucleotide binding protein, alpha q polypeptide (Gnaq), mRNA [NM_008139] |
KLA | .82 |
.82 |
.69 |
.64 |
.60 |
.55 |
.55 |
| ATP | 1.06 |
1.02 |
.87 |
.67 |
.50 |
.66 |
.57 |
| KLA/ATP | .82 |
.79 |
.66 |
.55 |
.41 |
.33 |
.48 |
|
Gnas |  |
AF107847 |
neuroendocrine-specific Golgi protein p55 isoform 1 (XLalphas) alternatively spliced mRNA, complete cds. [AF107847] |
KLA | 1.04 |
.94 |
1.00 |
1.05 |
1.04 |
.98 |
1.00 |
| ATP | .98 |
.97 |
.96 |
1.00 |
.99 |
.98 |
1.02 |
| KLA/ATP | 1.04 |
1.02 |
.96 |
.95 |
1.01 |
.96 |
1.01 |
|
Gnas |  |
AK017423 |
10 days neonate head cDNA, RIKEN full-length enriched library, clone:5530400H20 product:novel noncoding RNA overlapping the exon 1A, 1 and 2 of Gnas, full insert sequence. [AK017423] |
KLA | .85 |
1.08 |
.97 |
.92 |
1.05 |
1.03 |
1.08 |
| ATP | .99 |
1.30 |
2.11 |
1.73 |
1.23 |
1.01 |
1.02 |
| KLA/ATP | .96 |
1.06 |
1.58 |
1.34 |
1.29 |
1.05 |
.91 |
|
Gnas |  |
NM_001077510 |
GNAS (guanine nucleotide binding protein, alpha stimulating) complex locus (Gnas), transcript variant 8, mRNA [NM_001077510] |
KLA | .99 |
1.03 |
.97 |
.91 |
1.03 |
.95 |
.97 |
| ATP | 1.04 |
1.19 |
1.15 |
1.61 |
1.24 |
.91 |
1.00 |
| KLA/ATP | 1.06 |
.97 |
1.01 |
1.46 |
1.04 |
.85 |
1.01 |
|
Gnas |  |
S49980 |
gb|stimulatory G protein alpha subunit {clone WC-16} [mice, whole cochlea, mRNA Partial, 356 nt]. [S49980] |
KLA | .91 |
.88 |
1.03 |
.87 |
.90 |
.84 |
1.01 |
| ATP | 1.16 |
1.22 |
1.02 |
1.55 |
1.16 |
.80 |
.99 |
| KLA/ATP | 1.01 |
1.13 |
.86 |
1.12 |
.97 |
.85 |
1.08 |
|
Gper |  |
NM_029771 |
G protein-coupled estrogen receptor 1 (Gper), mRNA [NM_029771] |
KLA | .89 |
.95 |
.95 |
.96 |
1.01 |
1.16 |
1.16 |
| ATP | .98 |
.92 |
1.08 |
.95 |
1.03 |
1.16 |
1.08 |
| KLA/ATP | .88 |
.95 |
1.04 |
.91 |
1.05 |
1.07 |
1.02 |
|
Grb2 |  |
NM_008163 |
growth factor receptor bound protein 2 (Grb2), mRNA [NM_008163] |
KLA | .92 |
.88 |
.90 |
1.27 |
1.43 |
1.22 |
1.00 |
| ATP | 1.02 |
.83 |
.51 |
.42 |
.92 |
.70 |
.57 |
| KLA/ATP | .84 |
.77 |
.61 |
.56 |
1.56 |
1.49 |
.52 |
|
Grb2 |  |
U07617 |
Grb2 adaptor protein (grb2) mRNA, complete cds. [U07617] |
KLA | .83 |
.80 |
.95 |
1.13 |
1.38 |
1.36 |
1.06 |
| ATP | .84 |
.74 |
.51 |
.41 |
.82 |
.74 |
.59 |
| KLA/ATP | .77 |
.70 |
.57 |
.54 |
1.49 |
1.39 |
.53 |
|
Grm1 |  |
NM_016976 |
glutamate receptor, metabotropic 1 (Grm1), transcript variant 1, mRNA [NM_016976] |
KLA | 1.16 |
1.07 |
1.10 |
1.18 |
1.08 |
1.04 |
1.15 |
| ATP | 1.06 |
1.05 |
1.02 |
.99 |
1.00 |
1.09 |
1.02 |
| KLA/ATP | 1.04 |
1.12 |
1.06 |
1.11 |
1.10 |
1.32 |
1.35 |
|
Hbegf |  |
NM_010415 |
heparin-binding EGF-like growth factor (Hbegf), mRNA [NM_010415] |
KLA | 4.85 |
5.22 |
4.43 |
2.64 |
1.67 |
1.05 |
.85 |
| ATP | 1.16 |
1.29 |
9.30 |
21.54 |
19.63 |
14.93 |
4.45 |
| KLA/ATP | 5.32 |
5.51 |
13.94 |
26.41 |
22.89 |
13.95 |
5.50 |
|
Hras1 |  |
NM_008284 |
Harvey rat sarcoma virus oncogene 1 (Hras1), mRNA [NM_008284] |
KLA | .79 |
.82 |
.77 |
.82 |
.94 |
1.03 |
1.07 |
| ATP | 1.01 |
.95 |
.69 |
.83 |
.79 |
1.12 |
1.15 |
| KLA/ATP | .84 |
.77 |
.61 |
.65 |
.82 |
1.00 |
1.05 |
|
Hsp90aa1
|  |
NM_010480 |
heat shock protein 90, alpha (cytosolic), class A member 1 (Hsp90aa1), mRNA [NM_010480] |
KLA | .95 |
1.03 |
.90 |
.92 |
.80 |
.94 |
.99 |
| ATP | .96 |
.92 |
1.39 |
1.21 |
2.02 |
3.66 |
1.10 |
| KLA/ATP | .93 |
.92 |
1.32 |
1.01 |
1.85 |
2.21 |
1.20 |
|
Hsp90ab1
|  |
NM_008302 |
heat shock protein 90kDa alpha (cytosolic), class B member 1 (Hsp90ab1), mRNA [NM_008302] |
KLA | .93 |
1.02 |
.98 |
.82 |
.95 |
1.10 |
1.39 |
| ATP | 1.04 |
1.14 |
.92 |
1.32 |
1.19 |
1.02 |
.63 |
| KLA/ATP | 1.02 |
1.04 |
.80 |
1.12 |
.87 |
.86 |
.75 |
|
Hsp90b1 |  |
NM_011631 |
heat shock protein 90, beta (Grp94), member 1 (Hsp90b1), mRNA [NM_011631] |
KLA | .78 |
.83 |
.71 |
.69 |
.73 |
.69 |
.80 |
| ATP | 1.00 |
1.08 |
1.01 |
.94 |
.84 |
.84 |
.66 |
| KLA/ATP | .78 |
.82 |
.81 |
.73 |
.66 |
.68 |
.27 |
|
Hspa1a |  |
NM_010479 |
heat shock protein 1A (Hspa1a), mRNA [NM_010479] |
KLA | 7.88 |
6.99 |
4.47 |
5.18 |
7.81 |
11.47 |
4.14 |
| ATP | 1.88 |
5.62 |
43.42 |
58.76 |
55.53 |
28.89 |
9.13 |
| KLA/ATP | 7.40 |
7.62 |
28.23 |
54.12 |
70.14 |
43.09 |
22.49 |
|
Hspa1b |  |
NM_010478 |
heat shock protein 1B (Hspa1b), mRNA [NM_010478] |
KLA | 5.01 |
4.73 |
3.77 |
3.62 |
4.81 |
6.53 |
3.12 |
| ATP | 1.34 |
3.07 |
14.11 |
17.14 |
17.51 |
11.21 |
4.82 |
| KLA/ATP | 5.04 |
5.15 |
11.63 |
19.94 |
20.84 |
15.79 |
9.30 |
|
Hspa1l |  |
NM_013558 |
heat shock protein 1-like (Hspa1l), mRNA [NM_013558] |
KLA | .98 |
1.04 |
1.10 |
1.21 |
1.51 |
1.97 |
1.86 |
| ATP | 1.03 |
1.08 |
1.07 |
1.14 |
.93 |
1.21 |
1.89 |
| KLA/ATP | 1.06 |
1.01 |
.99 |
1.09 |
.97 |
1.39 |
2.87 |
|
Hspa2 |  |
NM_008301 |
heat shock protein 2 (Hspa2), transcript variant 1, mRNA [NM_008301] |
KLA | .98 |
.97 |
1.12 |
1.23 |
1.20 |
1.72 |
1.38 |
| ATP | 1.01 |
1.10 |
1.45 |
3.12 |
2.45 |
1.98 |
.98 |
| KLA/ATP | .99 |
1.12 |
1.52 |
2.60 |
2.89 |
2.62 |
1.18 |
|
Hspa8 |  |
NM_031165 |
heat shock protein 8 (Hspa8), mRNA [NM_031165] |
KLA | 1.00 |
.98 |
1.27 |
1.18 |
1.45 |
1.60 |
1.31 |
| ATP | 1.22 |
1.18 |
1.07 |
1.44 |
1.07 |
.53 |
.57 |
| KLA/ATP | 1.18 |
1.22 |
1.14 |
1.08 |
.93 |
.82 |
.77 |
|
Itpr1 |  |
NM_010585 |
inositol 1,4,5-triphosphate receptor 1 (Itpr1), mRNA [NM_010585] |
KLA | 3.66 |
3.69 |
6.74 |
8.11 |
7.08 |
4.40 |
1.22 |
| ATP | 1.08 |
.95 |
1.19 |
.94 |
1.09 |
1.00 |
.68 |
| KLA/ATP | 3.48 |
3.58 |
5.86 |
6.03 |
4.01 |
2.31 |
.97 |
|
Itpr2 |  |
NM_019923 |
inositol 1,4,5-triphosphate receptor 2 (Itpr2), transcript variant 1, mRNA [NM_019923] |
KLA | 1.41 |
1.38 |
1.43 |
1.42 |
1.30 |
1.07 |
1.01 |
| ATP | 1.00 |
1.00 |
.97 |
.97 |
1.07 |
1.15 |
1.06 |
| KLA/ATP | 1.39 |
1.48 |
1.64 |
1.42 |
1.07 |
.83 |
.95 |
|
Itpr3 |  |
NM_080553 |
inositol 1,4,5-triphosphate receptor 3 (Itpr3), mRNA [NM_080553] |
KLA | .55 |
.51 |
.45 |
.41 |
.34 |
.34 |
.45 |
| ATP | 1.01 |
.92 |
1.02 |
.57 |
.46 |
.34 |
1.22 |
| KLA/ATP | .56 |
.48 |
.48 |
.29 |
.33 |
.27 |
.65 |
|
Jun |  |
NM_010591 |
Jun oncogene (Jun), mRNA [NM_010591] |
KLA | 1.08 |
.96 |
1.09 |
1.09 |
.75 |
.88 |
.81 |
| ATP | 1.26 |
1.48 |
4.45 |
8.73 |
4.02 |
1.16 |
1.99 |
| KLA/ATP | 1.12 |
1.38 |
3.52 |
5.17 |
3.32 |
.49 |
1.42 |
|
Kcnj3 |  |
BC068167 |
potassium inwardly-rectifying channel, subfamily J, member 3, mRNA (cDNA clone MGC:92970 IMAGE:30543982), complete cds [BC068167] |
KLA | .99 |
.97 |
1.01 |
.94 |
.97 |
.99 |
.99 |
| ATP | 1.06 |
1.01 |
1.03 |
.82 |
1.01 |
1.00 |
.94 |
| KLA/ATP | .98 |
.91 |
.99 |
.99 |
1.01 |
1.11 |
.97 |
|
Kcnj3 |  |
NM_008426 |
potassium inwardly-rectifying channel, subfamily J, member 3 (Kcnj3), mRNA [NM_008426] |
KLA | 1.05 |
.99 |
1.04 |
1.02 |
1.02 |
1.04 |
.94 |
| ATP | 1.00 |
1.01 |
1.02 |
.99 |
.96 |
1.03 |
1.04 |
| KLA/ATP | 1.00 |
.98 |
1.03 |
1.02 |
1.02 |
.96 |
1.06 |
|
Kcnj5 |  |
NM_010605 |
potassium inwardly-rectifying channel, subfamily J, member 5 (Kcnj5), mRNA [NM_010605] |
KLA | 1.06 |
1.07 |
.97 |
.97 |
.99 |
1.05 |
.98 |
| ATP | .96 |
1.11 |
1.09 |
.98 |
.95 |
1.03 |
1.05 |
| KLA/ATP | .98 |
1.00 |
1.10 |
.98 |
1.07 |
.96 |
1.02 |
|
Kcnj6 |  |
NM_001025585 |
potassium inwardly-rectifying channel, subfamily J, member 6 (Kcnj6), transcript variant Girk2B, mRNA [NM_001025585] |
KLA | .97 |
.96 |
.95 |
.96 |
.98 |
.96 |
.95 |
| ATP | 1.00 |
.98 |
1.02 |
1.00 |
.98 |
.96 |
.97 |
| KLA/ATP | .98 |
.95 |
.99 |
.96 |
.98 |
.93 |
.96 |
|
Kcnj6 |  |
NM_010606 |
potassium inwardly-rectifying channel, subfamily J, member 6 (Kcnj6), transcript variant Girk2A-1, mRNA [NM_010606] |
KLA | .96 |
1.03 |
.97 |
.98 |
.97 |
.99 |
1.07 |
| ATP | 1.08 |
.99 |
.99 |
1.05 |
.96 |
1.04 |
.97 |
| KLA/ATP | 1.01 |
.92 |
1.03 |
1.03 |
1.04 |
1.03 |
1.08 |
|
Kcnj9 |  |
AK007011 |
adult male testis cDNA, RIKEN full-length enriched library, clone:1700085N21 product:unclassifiable, full insert sequence. [AK007011] |
KLA | 1.00 |
1.03 |
.98 |
1.02 |
.95 |
1.09 |
1.01 |
| ATP | .97 |
.92 |
1.03 |
1.11 |
1.02 |
.95 |
1.01 |
| KLA/ATP | 1.01 |
.98 |
.98 |
1.05 |
1.07 |
1.03 |
1.02 |
|
Kcnj9 |  |
NM_008429 |
potassium inwardly-rectifying channel, subfamily J, member 9 (Kcnj9), mRNA [NM_008429] |
KLA | 1.03 |
1.06 |
1.06 |
1.07 |
1.09 |
.95 |
1.00 |
| ATP | 1.02 |
.93 |
.93 |
1.14 |
1.07 |
.98 |
.95 |
| KLA/ATP | 1.03 |
.99 |
.99 |
1.02 |
1.02 |
.96 |
.96 |
|
Kras |  |
NM_021284 |
v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (Kras), mRNA [NM_021284] |
KLA | .53 |
.49 |
.40 |
.42 |
.49 |
.95 |
1.05 |
| ATP | .98 |
1.01 |
1.16 |
1.17 |
1.39 |
1.29 |
1.74 |
| KLA/ATP | .50 |
.47 |
.50 |
.56 |
1.00 |
1.24 |
1.58 |
|
Map2k1 |  |
NM_008927 |
mitogen-activated protein kinase kinase 1 (Map2k1), mRNA [NM_008927] |
KLA | 1.82 |
2.00 |
2.31 |
2.03 |
2.51 |
2.20 |
1.51 |
| ATP | .99 |
1.14 |
.81 |
.87 |
.90 |
1.57 |
1.11 |
| KLA/ATP | 1.90 |
2.03 |
1.50 |
1.93 |
1.63 |
2.03 |
2.06 |
|
Map2k2 |  |
NM_023138 |
mitogen-activated protein kinase kinase 2 (Map2k2), mRNA [NM_023138] |
KLA | .96 |
1.01 |
1.09 |
.99 |
1.11 |
1.15 |
1.42 |
| ATP | 1.07 |
1.05 |
.74 |
.86 |
1.04 |
1.16 |
1.21 |
| KLA/ATP | 1.14 |
1.03 |
.68 |
.78 |
.85 |
1.01 |
1.20 |
|
Mapk1 |  |
NM_001038663 |
mitogen-activated protein kinase 1 (Mapk1), transcript variant 2, mRNA [NM_001038663] |
KLA | .97 |
1.03 |
.93 |
.86 |
.79 |
1.01 |
1.04 |
| ATP | .96 |
1.18 |
1.01 |
1.13 |
.84 |
1.04 |
1.16 |
| KLA/ATP | .99 |
.99 |
.84 |
.87 |
.63 |
.96 |
1.26 |
|
Mapk1 |  |
NM_011949 |
mitogen-activated protein kinase 1 (Mapk1), transcript variant 1, mRNA [NM_011949] |
KLA | .88 |
.80 |
.80 |
.73 |
.75 |
.76 |
.65 |
| ATP | .97 |
.96 |
1.06 |
.88 |
.90 |
.68 |
.48 |
| KLA/ATP | .82 |
.81 |
.78 |
.65 |
.64 |
.64 |
.45 |
|
Mapk3 |  |
NM_011952 |
mitogen-activated protein kinase 3 (Mapk3), mRNA [NM_011952] |
KLA | .81 |
.85 |
.88 |
.72 |
.79 |
.73 |
.90 |
| ATP | 1.13 |
1.30 |
.92 |
1.48 |
1.08 |
.68 |
1.03 |
| KLA/ATP | 1.01 |
1.01 |
.66 |
1.13 |
.77 |
.77 |
1.16 |
|
Mm.21312 8 |  |
141801344 |
Unknown |
KLA | .96 |
.95 |
.83 |
.77 |
.52 |
.99 |
1.32 |
| ATP | .80 |
.82 |
1.09 |
.80 |
.83 |
1.19 |
1.46 |
| KLA/ATP | .78 |
.92 |
.98 |
.62 |
.71 |
.94 |
1.41 |
|
Mm.25381 9 |  |
118130676 |
Unknown |
KLA | 1.81 |
1.88 |
1.96 |
1.62 |
1.89 |
2.44 |
1.56 |
| ATP | .92 |
.91 |
1.24 |
1.01 |
1.16 |
2.06 |
1.95 |
| KLA/ATP | 1.62 |
1.86 |
1.86 |
1.41 |
1.89 |
2.37 |
1.97 |
|
Mm.28968 1 |  |
6754177 |
Unknown |
KLA | 5.70 |
5.98 |
5.26 |
3.13 |
1.73 |
.87 |
.76 |
| ATP | 1.12 |
1.23 |
10.71 |
22.34 |
24.13 |
18.42 |
4.28 |
| KLA/ATP | 5.68 |
6.39 |
18.15 |
29.48 |
26.96 |
19.85 |
6.17 |
|
Mm.41137
|  |
148747308 |
Unknown |
KLA | 1.03 |
1.00 |
.95 |
.92 |
1.04 |
.98 |
.96 |
| ATP | 1.02 |
.98 |
.98 |
.90 |
.95 |
.92 |
1.07 |
| KLA/ATP | .91 |
.89 |
1.01 |
.95 |
1.00 |
.96 |
.99 |
|
Mm.41274 5 |  |
110681696 |
Unknown |
KLA | .97 |
1.07 |
1.11 |
1.07 |
1.38 |
1.63 |
1.35 |
| ATP | 1.06 |
1.09 |
1.05 |
1.29 |
1.04 |
.50 |
.56 |
| KLA/ATP | 1.11 |
1.12 |
1.04 |
1.11 |
.92 |
.83 |
.74 |
|
Mm.44160 1 |  |
145966786 |
Unknown |
KLA | 1.08 |
.94 |
1.01 |
.97 |
.79 |
.78 |
.71 |
| ATP | 1.09 |
.92 |
1.10 |
.75 |
.65 |
.92 |
.69 |
| KLA/ATP | 1.01 |
.92 |
1.16 |
.81 |
.69 |
.56 |
.63 |
|
Mmp2 |  |
NM_008610 |
matrix metallopeptidase 2 (Mmp2), mRNA [NM_008610] |
KLA | 1.12 |
1.24 |
1.48 |
1.26 |
1.44 |
1.19 |
1.09 |
| ATP | 1.05 |
1.01 |
1.07 |
1.08 |
.93 |
1.01 |
1.14 |
| KLA/ATP | 1.23 |
1.26 |
1.16 |
1.15 |
.95 |
1.11 |
1.04 |
|
Mmp9 |  |
NM_013599 |
matrix metallopeptidase 9 (Mmp9), mRNA [NM_013599] |
KLA | 1.49 |
1.65 |
1.43 |
1.32 |
1.46 |
1.33 |
2.10 |
| ATP | 1.03 |
1.05 |
1.12 |
1.36 |
1.17 |
2.27 |
5.92 |
| KLA/ATP | 1.51 |
1.64 |
1.35 |
1.78 |
1.34 |
1.20 |
2.96 |
|
Nos3 |  |
NM_008713 |
nitric oxide synthase 3, endothelial cell (Nos3), mRNA [NM_008713] |
KLA | .83 |
.79 |
.76 |
.78 |
.77 |
.85 |
.96 |
| ATP | 1.03 |
1.09 |
1.03 |
1.02 |
.85 |
.96 |
1.84 |
| KLA/ATP | .80 |
.78 |
.79 |
.80 |
.79 |
.78 |
.91 |
|
Nras |  |
NM_010937 |
neuroblastoma ras oncogene (Nras), mRNA [NM_010937] |
KLA | 1.20 |
1.22 |
1.27 |
1.20 |
1.09 |
.91 |
.84 |
| ATP | .98 |
.91 |
.69 |
.61 |
.59 |
.67 |
.78 |
| KLA/ATP | 1.22 |
1.14 |
.97 |
.79 |
.73 |
.61 |
.72 |
|
Oprm1 |  |
NM_001039652 |
opioid receptor, mu 1 (Oprm1), mRNA [NM_001039652] |
KLA | .98 |
1.04 |
.94 |
.96 |
.93 |
.94 |
1.03 |
| ATP | .89 |
.92 |
1.06 |
.98 |
1.00 |
1.04 |
1.01 |
| KLA/ATP | .94 |
.97 |
1.05 |
1.00 |
1.02 |
1.01 |
1.00 |
|
Pik3ca |  |
ENSMUST00000108243 |
ens|Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha isoform (EC 2.7.1.153) (PI3-kinase p110 subunit alpha) (PtdIns-3- kinase p110) (PI3K). [Source:Uniprot/SWISSPROT;Acc:P42337] [ENSMUST00000108243] |
KLA | 1.07 |
1.01 |
.91 |
.90 |
.98 |
.96 |
.86 |
| ATP | 1.03 |
.87 |
1.12 |
.63 |
1.22 |
1.86 |
.60 |
| KLA/ATP | 1.05 |
.82 |
.91 |
.61 |
1.17 |
1.26 |
.63 |
|
Pik3ca |  |
NM_008839 |
phosphatidylinositol 3-kinase, catalytic, alpha polypeptide (Pik3ca), mRNA [NM_008839] |
KLA | 1.15 |
1.11 |
1.05 |
.82 |
.99 |
1.03 |
1.27 |
| ATP | .98 |
1.00 |
.79 |
.75 |
.96 |
1.32 |
1.10 |
| KLA/ATP | 1.10 |
.98 |
.64 |
.72 |
.80 |
1.20 |
1.41 |
|
Pik3cb |  |
NM_029094 |
phosphatidylinositol 3-kinase, catalytic, beta polypeptide (Pik3cb), mRNA [NM_029094] |
KLA | 1.06 |
1.06 |
1.03 |
.73 |
.68 |
.98 |
1.69 |
| ATP | 1.04 |
1.21 |
.95 |
1.02 |
.85 |
.93 |
1.73 |
| KLA/ATP | 1.15 |
1.27 |
.73 |
.83 |
.58 |
.81 |
1.81 |
|
Pik3cd |  |
NM_008840 |
phosphatidylinositol 3-kinase catalytic delta polypeptide (Pik3cd), transcript variant 1, mRNA [NM_008840] |
KLA | 2.28 |
2.42 |
3.10 |
4.17 |
3.35 |
2.31 |
1.34 |
| ATP | 1.02 |
.91 |
.99 |
.63 |
.30 |
.67 |
.80 |
| KLA/ATP | 2.14 |
2.23 |
2.70 |
1.51 |
1.17 |
.85 |
.72 |
|
Pik3cd |  |
U86587 |
phosphatidylinositol 3-kinase catalytic subunit p110 delta mRNA, complete cds. [U86587] |
KLA | 2.21 |
2.24 |
3.71 |
3.17 |
3.67 |
2.66 |
1.48 |
| ATP | 1.00 |
1.03 |
.93 |
.96 |
.46 |
.75 |
.97 |
| KLA/ATP | 2.27 |
2.32 |
1.97 |
2.02 |
1.01 |
.99 |
.98 |
|
Pik3cg |  |
NM_020272 |
phosphoinositide-3-kinase, catalytic, gamma polypeptide (Pik3cg), mRNA [NM_020272] |
KLA | .53 |
.53 |
.61 |
.64 |
.97 |
.86 |
.79 |
| ATP | 1.01 |
1.13 |
.88 |
.89 |
.52 |
.53 |
.53 |
| KLA/ATP | .58 |
.53 |
.43 |
.60 |
.40 |
.43 |
.62 |
|
Pik3r1 |  |
NM_001077495 |
phosphatidylinositol 3-kinase, regulatory subunit, polypeptide 1 (p85 alpha) (Pik3r1), transcript variant 2, mRNA [NM_001077495] |
KLA | 1.05 |
1.07 |
1.03 |
1.00 |
1.01 |
1.20 |
.85 |
| ATP | .97 |
1.02 |
1.48 |
1.42 |
1.76 |
1.33 |
1.23 |
| KLA/ATP | 1.11 |
1.12 |
1.06 |
1.17 |
1.24 |
.99 |
1.12 |
|
Pik3r2 |  |
NM_008841 |
phosphatidylinositol 3-kinase, regulatory subunit, polypeptide 2 (p85 beta) (Pik3r2), mRNA [NM_008841] |
KLA | .50 |
.50 |
.48 |
.43 |
.46 |
.66 |
.75 |
| ATP | .78 |
.68 |
.45 |
.43 |
.28 |
.57 |
1.37 |
| KLA/ATP | .49 |
.38 |
.32 |
.33 |
.38 |
.67 |
1.10 |
|
Pik3r3 |  |
NM_181585 |
phosphatidylinositol 3 kinase, regulatory subunit, polypeptide 3 (p55) (Pik3r3), mRNA [NM_181585] |
KLA | 1.59 |
1.49 |
1.37 |
1.17 |
1.05 |
1.55 |
1.41 |
| ATP | 1.12 |
1.00 |
1.33 |
1.70 |
2.01 |
2.37 |
2.02 |
| KLA/ATP | 1.63 |
1.54 |
1.58 |
1.70 |
2.43 |
2.68 |
1.92 |
|
Pik3r5 |  |
NM_177320 |
phosphoinositide-3-kinase, regulatory subunit 5, p101 (Pik3r5), mRNA [NM_177320] |
KLA | 3.57 |
3.58 |
4.16 |
3.54 |
4.11 |
2.59 |
2.39 |
| ATP | 1.08 |
1.08 |
.93 |
1.67 |
3.11 |
1.88 |
1.34 |
| KLA/ATP | 3.91 |
3.70 |
3.30 |
3.80 |
2.70 |
2.04 |
3.00 |
|
Plcb1 |  |
AK129166 |
mRNA for mKIAA0581 protein [AK129166] |
KLA | 1.02 |
.98 |
.91 |
.91 |
.92 |
.95 |
.89 |
| ATP | 1.03 |
1.02 |
1.02 |
1.01 |
.90 |
1.02 |
1.04 |
| KLA/ATP | .98 |
.97 |
.91 |
.93 |
.92 |
1.01 |
1.16 |
|
Plcb1 |  |
NM_019677 |
phospholipase C, beta 1 (Plcb1), mRNA [NM_019677] |
KLA | .99 |
.94 |
.95 |
.97 |
.93 |
.92 |
.91 |
| ATP | 1.00 |
.96 |
.99 |
.95 |
.99 |
1.03 |
.98 |
| KLA/ATP | .93 |
.96 |
.94 |
.93 |
.87 |
1.00 |
1.06 |
|
Plcb2 |  |
NM_177568 |
phospholipase C, beta 2 (Plcb2), mRNA [NM_177568] |
KLA | .70 |
.68 |
.64 |
.67 |
.65 |
.76 |
.88 |
| ATP | .95 |
.94 |
1.04 |
.94 |
.72 |
.57 |
1.19 |
| KLA/ATP | .69 |
.68 |
.72 |
.63 |
.65 |
.55 |
.70 |
|
Plcb3 |  |
NM_008874 |
phospholipase C, beta 3 (Plcb3), mRNA [NM_008874] |
KLA | 1.72 |
1.78 |
1.82 |
1.65 |
1.67 |
1.44 |
1.21 |
| ATP | .97 |
1.04 |
.81 |
.87 |
.78 |
.88 |
.94 |
| KLA/ATP | 1.69 |
1.89 |
1.44 |
1.66 |
1.12 |
.73 |
.93 |
|
Plcb4 |  |
AK082509 |
0 day neonate cerebellum cDNA, RIKEN full-length enriched library, clone:C230058B11 product:unclassifiable, full insert sequence. [AK082509] |
KLA | 1.06 |
1.03 |
.97 |
.98 |
1.02 |
1.01 |
.99 |
| ATP | .99 |
1.07 |
1.09 |
.95 |
.97 |
.97 |
1.02 |
| KLA/ATP | .98 |
1.00 |
1.03 |
.96 |
1.02 |
.91 |
.98 |
|
Plcb4 |  |
NM_013829 |
phospholipase C, beta 4 (Plcb4), mRNA [NM_013829] |
KLA | .88 |
.94 |
.81 |
.82 |
.81 |
.86 |
1.01 |
| ATP | 1.00 |
1.01 |
.92 |
.93 |
.88 |
.85 |
.89 |
| KLA/ATP | .97 |
.94 |
.78 |
.80 |
.78 |
.86 |
.97 |
|
Prkaca |  |
NM_008854 |
protein kinase, cAMP dependent, catalytic, alpha (Prkaca), mRNA [NM_008854] |
KLA | .71 |
.74 |
.72 |
.70 |
.72 |
.84 |
.85 |
| ATP | 1.05 |
.98 |
.89 |
.92 |
.76 |
.60 |
1.02 |
| KLA/ATP | .79 |
.74 |
.55 |
.65 |
.60 |
.65 |
.93 |
|
Prkacb |  |
NM_011100 |
protein kinase, cAMP dependent, catalytic, beta (Prkacb), mRNA [NM_011100] |
KLA | .69 |
.70 |
.66 |
.58 |
.51 |
.55 |
.59 |
| ATP | 1.02 |
1.19 |
.97 |
1.01 |
.69 |
.38 |
.56 |
| KLA/ATP | .72 |
.73 |
.57 |
.62 |
.47 |
.41 |
.45 |
|
Prkcd |  |
NM_011103 |
protein kinase C, delta (Prkcd), mRNA [NM_011103] |
KLA | 1.72 |
1.84 |
1.90 |
1.68 |
2.01 |
1.61 |
1.64 |
| ATP | 1.00 |
1.03 |
.68 |
.81 |
1.38 |
1.26 |
.98 |
| KLA/ATP | 1.77 |
1.79 |
1.16 |
1.19 |
1.33 |
1.25 |
1.56 |
|
Prkx |  |
NM_016979 |
protein kinase, X-linked (Prkx), mRNA [NM_016979] |
KLA | 3.61 |
3.79 |
4.67 |
4.66 |
4.85 |
4.19 |
1.43 |
| ATP | .98 |
.90 |
.63 |
.61 |
1.12 |
1.90 |
1.29 |
| KLA/ATP | 3.56 |
3.36 |
2.62 |
2.06 |
2.26 |
2.87 |
2.31 |
|
Raf1 |  |
AK036317 |
16 days neonate cerebellum cDNA, RIKEN full-length enriched library, clone:9630056E02 product:v-raf-1 leukemia viral oncogene 1, full insert sequence. [AK036317] |
KLA | 1.47 |
1.34 |
1.55 |
1.29 |
1.59 |
1.32 |
1.46 |
| ATP | 1.05 |
.98 |
.54 |
.63 |
3.32 |
2.07 |
1.01 |
| KLA/ATP | 1.57 |
1.33 |
.79 |
.96 |
2.26 |
1.38 |
1.35 |
|
Raf1 |  |
NM_029780 |
v-raf-leukemia viral oncogene 1 (Raf1), mRNA [NM_029780] |
KLA | 1.65 |
1.64 |
1.93 |
1.77 |
1.77 |
1.72 |
1.81 |
| ATP | .95 |
.96 |
.83 |
.80 |
2.22 |
2.92 |
1.19 |
| KLA/ATP | 1.68 |
1.64 |
1.39 |
1.32 |
1.85 |
2.50 |
2.06 |
|
Shc1 |  |
NM_011368 |
src homology 2 domain-containing transforming protein C1 (Shc1), transcript variant 2, mRNA [NM_011368] |
KLA | .88 |
.87 |
.86 |
.83 |
1.09 |
1.11 |
1.12 |
| ATP | 1.04 |
1.25 |
.85 |
1.17 |
.93 |
1.16 |
1.00 |
| KLA/ATP | .93 |
.96 |
.62 |
.96 |
.75 |
1.25 |
1.19 |
|
Shc2 |  |
NM_001024539 |
src homology 2 domain-containing transforming protein C2 (Shc2), mRNA [NM_001024539] |
KLA | 1.19 |
1.25 |
1.22 |
1.16 |
1.15 |
1.14 |
.98 |
| ATP | 1.04 |
1.14 |
1.15 |
1.53 |
1.29 |
1.06 |
1.09 |
| KLA/ATP | 1.26 |
1.24 |
1.26 |
1.49 |
1.31 |
1.30 |
1.30 |
|
Shc3 |  |
NM_009167 |
src homology 2 domain-containing transforming protein C3 (Shc3), mRNA [NM_009167] |
KLA | 1.00 |
.98 |
1.06 |
1.06 |
1.12 |
1.08 |
1.04 |
| ATP | .99 |
1.02 |
1.00 |
1.05 |
1.00 |
1.08 |
1.08 |
| KLA/ATP | 1.08 |
1.06 |
1.01 |
1.06 |
1.03 |
1.12 |
1.41 |
|
Shc4 |  |
NM_199022 |
SHC (Src homology 2 domain containing) family, member 4 (Shc4), mRNA [NM_199022] |
KLA | 1.03 |
1.03 |
1.01 |
1.06 |
1.09 |
1.03 |
1.06 |
| ATP | .99 |
1.00 |
1.03 |
1.02 |
1.04 |
1.04 |
1.01 |
| KLA/ATP | .98 |
.97 |
1.06 |
1.05 |
1.00 |
1.00 |
1.14 |
|
Sos1 |  |
NM_009231 |
Son of sevenless homolog 1 (Drosophila) (Sos1), mRNA [NM_009231] |
KLA | 2.36 |
2.40 |
3.42 |
3.15 |
2.78 |
1.81 |
1.71 |
| ATP | .99 |
1.00 |
.99 |
1.15 |
1.14 |
1.25 |
1.24 |
| KLA/ATP | 2.41 |
2.26 |
1.95 |
2.44 |
1.47 |
1.66 |
1.37 |
|
Sos2 |  |
XM_127051 |
gb|PREDICTED: Mus musculus Son of sevenless homolog 2 (Drosophila) (Sos2), mRNA [XM_127051] |
KLA | .81 |
.77 |
.79 |
.92 |
1.04 |
1.06 |
1.20 |
| ATP | 1.00 |
1.00 |
1.09 |
.79 |
.68 |
.81 |
.94 |
| KLA/ATP | .77 |
.69 |
.71 |
.60 |
.64 |
.77 |
1.07 |
|
Sp1 |  |
NM_013672 |
trans-acting transcription factor 1 (Sp1), mRNA [NM_013672] |
KLA | .81 |
.75 |
.67 |
.79 |
.89 |
1.00 |
.84 |
| ATP | .96 |
1.01 |
1.13 |
.93 |
1.30 |
1.51 |
.84 |
| KLA/ATP | .73 |
.74 |
.81 |
.66 |
1.38 |
1.34 |
1.20 |
|
Src |  |
NM_009271 |
Rous sarcoma oncogene (Src), transcript variant 1, mRNA [NM_009271] |
KLA | 6.99 |
7.23 |
7.54 |
5.99 |
5.34 |
3.39 |
3.00 |
| ATP | 1.02 |
1.06 |
1.06 |
2.08 |
4.41 |
5.03 |
3.97 |
| KLA/ATP | 7.44 |
7.51 |
5.48 |
6.24 |
4.86 |
5.86 |
7.90 |
|